Sacubitril/Valsartan Initiation Among Veterans Who Are Renin‐Angiotensin‐Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction
Open Access
- 19 October 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 10 (20) , e020474
Abstract
Background: Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF). Our objective was to describe the sacubitril/valsartan initiation rate, associated characteristics, and 6‐month follow‐up dosing among veterans with HFrEF who are renin‐angiotensin‐aldosterone system inhibitor (RAASi) naïve. Methods and Results: Retrospective cohort study of veterans with HFrEF who are RAASi naïve defined as left ventricular ejection fraction (LVEF) ≤40%; ≥1 in/outpatient heart failure visit, first RAASi (sacubitril/valsartan, angiotensin‐converting enzyme inhibitor [ACEI]), or angiotensin‐II receptor blocker [ARB]) fill from July 2015 to June 2019. Characteristics associated with sacubitril/valsartan initiation were identified using Poisson regression models. From July 2015 to June 2019, we identified 3458 sacubitril/valsartan and 29 367 ACEI or ARB initiators among veterans with HFrEF who are RAASi naïve. Sacubitril/valsartan initiation increased from 0% to 26.5%. Sacubitril/valsartan (versus ACEI or ARB) initiators were less likely to have histories of stroke, myocardial infarction, or hypertension and more likely to be older and have diabetes mellitus and lower LVEF. At 6‐month follow‐up, the prevalence of ≥50% target daily dose for sacubitril/valsartan, ACEI, and ARB initiators was 23.5%, 43.2%, and 47.1%, respectively. Conclusions: Sacubitril/valsartan initiation for HFrEF in the Veterans Administration increased in the 4 years immediately following Food and Drug Administration approval. Sacubitril/valsartan (versus ACEI or ARB) initiators had fewer baseline cardiovascular comorbidities and the lowest proportion on ≥50% target daily dose at 6‐month follow‐up. Identifying the reasons for lower follow‐up dosing of sacubitril/valsartan could support guideline recommendations and quality improvement strategies for patients with HFrEF.Keywords
This publication has 22 references indexed in Scilit:
- Adoption of Sacubitril/Valsartan for the Management of Patients With Heart FailureCirculation: Heart Failure, 2018
- 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of AmericaCirculation, 2017
- Unlocking echocardiogram measurements for heart disease research through natural language processingBMC Cardiovascular Disorders, 2017
- Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection FractionJACC: Heart Failure, 2017
- Medication acquisition by veterans dually eligible for Veterans Affairs and Medicare Part D pharmacy benefitsAmerican Journal of Health-System Pharmacy, 2017
- Efficacy of Sacubitril/Valsartan vs. Enalapril at Lower than Target Doses in Heart Failure with Reduced Ejection Fraction: The PARADIGM-HF TrialEuropean Journal of Heart Failure, 2016
- An introduction to implementation science for the non-specialistBMC Psychology, 2015
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialThe Lancet, 2012
- ACCF/AHA/AMA-PCPI 2011 Performance Measures for Adults With Heart FailureCirculation, 2012
- Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk FactorsMedical Care, 2005